Gastrointestinal and Hepatic Complications

Thomas' Hematopoietic Cell Transplantation: Fifth Edition

Volumn 2-2, Issue , 2016, Pages 1140-1160

  Hockenbery, David M ^a   Strasser, Simone I ^b   McDonald, George B ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Adenovirus infections; Cytomegalovirus infections; Gastrointestinal infections; Hematopoietic cell transplantation; Liver disease; Liver presentations of GVHD; Long term transplant survivors; Norovirus infections; Protracted acute GVHD

Indexed keywords

EID: 84962311220     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118416426.ch94     Document Type: Chapter

References (252)

1. McDonald GB. Hepatobiliary complications of hematopoietic cell transplantation, years on. Hepatology 2010; 51: 1450-1460.
2. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic- cell transplantation. N Engl J Med 2010; 363: 2091-2101.
3. Fries BC, Riddell SR, Kim HW, et al. Cytomegalovirus disease before hematopoietic cell transplantation as a risk for complications after transplantation. Biol Blood Marrow Transplant 2005; 11: 136-148.
4. Otero Lopez-Cubero S, Sullivan KM, McDonald GB. Course of Crohn's disease after allogeneic marrow transplantation. Gastroenterology 1998; 114: 433-440.
5. Ditschkowski M, Einsele H, Schwerdtfeger R, et al. Improvement of inflammatory bowel disease after allogeneic stem-cell transplantation. Transplantation 2003; 75: 1745-1747.
6. Burt RK, Craig RM, Milanetti F, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood 2010; 116: 6123-6132.
7. Kang G, Srivastava A, Pulimood AB, et al. Etiology of diarrhea in patients undergoing allogeneic bone marrow transplantation in South India. Transplantation 2002; 73: 1247-1251.
8. McLauchlin J, Amar CFL, Pedraza-Diaz S, et al. Polymerase chain reaction-based diagnosis of infection with Cryptosporidium in children with primary immunodeficiencies. Pediatr Infect Dis J 2003; 22: 329-335.
9. Muller CI, Zeiser R, Grullich C, et al. Intestinal cryptosporidiosis mimicking acute graft-versus-host disease following matched unrelated hematopoietic stem cell transplantation. Transplantation 2004; 77: 1478-1479.
10. Sebastian E, Martin J, McDonald GB, et al. Cryptosporidium parvum infection vs GVHD after hematopoietic SCT: diagnosis by PCR with resolution of symptoms. Bone Marrow Transplant 2011; 46: 612-614.
11. Schwartz S, Vergoulidou M, Schreier E, et al. Norovirus gastroenteritis causes severe and lethal complications after chemotherapy and hematopoietic stem cell transplantation. Blood 2011; 117: 5850-5856.
12. Perret C, Harris PR, Rivera M, et al. Refractory enteric amebiasis in pediatric patients with acute graft-versus-host disease after allogeneic bone marrow transplantation. J Pediatr Gastroenterol Nutr 2000; 31: 86-90.
13. Dimicoli S, Bensoussan D, Latger-Cannard V, et al. Complete recovery from Cryptosporidium parvum infection with gastroenteritis and sclerosing cholangitis after successful bone marrow transplantation in two brothers with X-linked hyper-IgM syndrome. Bone Marrow Transplant 2003; 32: 733-737.
14. Gorkiewicz G. Nosocomial and antibiotic-associated diarrhoea caused by organisms other than Clostridium difficile. Int J Antimicrob Agents 2009; 33(Suppl. 1): S37-S41.
15. Rao A, Kamani N, Filipovich A, et al. Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. Blood 2007; 109: 383-385.
16. Tack GJ, Wondergem MJ, Al-Toma A, et al. Auto-SCT in refractory celiac disease type II patients unresponsive to cladribine therapy. Bone Marrow Transplant 2011; 46: 840-846.
17. Cohen JS, Paz IB, O'Donnell MR, Ellenhorn JD. Treatment of perianal infection following bone marrow transplantation. Dis Colon Rectum 1996; 39: 981-985.
18. Lehrnbecher T, Marshall D, Gao C, Chanock SJ. A second look at anorectal infections in cancer patients in a large cancer institute: the success of early intervention with antibiotics and surgery. Infection 2002; 30: 272-276.
19. Ryan C, De Gascun CF, Powell C, et al. Cytomegalovirus-induced cutaneous vasculopathy and perianal ulceration. J Am Acad Dermatol 2011; 64: 1216-1218.
20. Deschenes M, Laneuville P. Pre-emptive use of lamivudine in bone marrow transplantation with chronic hepatitis B virus infection. Hepatology 2004; 39: 867-868.
21. Said ZN. An overview of occult hepatitis B virus infection. World J Gastroenterol 2011; 17: 1927-1938.
22. Lau GK, Suri D, Liang R, et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 2002; 122: 614-624.
23. Beckerich F, Hezode C, Robin C, et al. New nucleotide polymerase inhibitors to rapidly permit hematopoietic stem cell donation from a positive HCV-RNA donor. Blood 2014; 124: 2613-2614.
24. Hsiao HH, Liu YC, Wang HC, et al. Hepatitis C transmission from viremic donors in hematopoietic stem cell transplant. Transplant infectious disease 2014; 16: 1003-1006.
25. Strasser SI, Myerson D, Spurgeon CL, et al. Hepatitis C virus infection after bone marrow transplantation: a cohort study with 10 year follow-up. Hepatology 1999; 29: 1893-1899.
26. Evans AT, Loeb KR, Shulman HM, et al. Fibrosing cholestatic hepatitis C after hematopoietic cell transplantation: report of 3 fatal cases. American Journal of Surgical Pathology 2015; 39: 212-220.
27. Tomblyn M, Chen M, Kukreja M, et al. No increased mortality from donor or recipient hepatitis B- and/or hepatitis C-positive serostatus after related-donor allogeneic hematopoietic cell transplantation. Transplant Infectious Disease 2012; 14: 468-478.
28. Hogan WJ, Maris M, Storer B, et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood 2004; 103: 78-84.
29. Wong KM, Atenafu EG, Kim D, et al. Incidence and risk factors for early hepatotoxicity and its impact on survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18: 1589-1599.
30. Martinez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology 2011; 53: 325-335.
31. Hamidieh AA, Shazad B, Ostovaneh MR, et al. Noninvasive measurement of liver fibrosis using transient elastography in pediatric patients with major thalassemia who are candidates for hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014; 20: 1912-1917.
32. Auberger J, Graziadei I, Clausen J, et al. Non-invasive transient elastography for the prediction of liver toxicity following hematopoietic SCT. Bone Marrow Transplantation 2013; 48: 159-160.
33. Picardi M, De Rosa G, Selleri C, et al. Clinical relevance of intrahepatic hepatitis B virus DNA in HBsAg-negative HBcAb-positive patients undergoing hematopoietic stem cell transplantation for hematological malignancies. Transplantation 2006; 82: 141-142.
34. Carpenter PA, Huang ML, McDonald GB. Activation of occult hepatitis B from a seronegative patient after hematopoietic cell transplant: a cautionary tale. Blood 2002; 99: 4245-4246.
35. McDonald GB, Frieze D. A problem-oriented approach to liver disease in oncology patients. Gut 2008; 57: 987-1003.
36. McKoy JM, Angelotta C, Bennett CL, et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res 2007; 31: 599-604.
37. Azie N, Neofytos D, Pfaller M, et al. The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis 2012; 73: 293-300.
38. Wermke M, Schmidt A, Middeke JM, et al. MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation. Clin Cancer Res 2012; 18: 6460-6468.
39. Kida A, McDonald GB. Gastrointestinal, hepatobiliary, pancreatic, and ironrelated diseases in long-term survivors of allogeneic hematopoietic cell transplantation. Semin Hematol 2012; 49: 43-58.
40. DiBaise JK, Lyden E, Tarantolo SR, et al. A prospective study of gastric emptying and its relationship to the development of nausea, vomiting, and anorexia after autologous stem cell transplantation. Am J Gastroenterol 2005; 100: 1571-1577.
41. Eagle DA, Gian V, Lauwers GY, et al. Gastroparesis following bone marrow transplantation. Bone Marrow Transplant 2001; 28: 59-62.
42. Johansson JE, Abrahamsson H, Ekman T. Gastric emptying after autologous haemopoietic stem-cell transplantation: a prospective trial. Bone Marrow Transplant 2003; 32: 815-819.
43. Lilleby K, Garcia P, Gooley T, et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 37: 1031-1035.
44. Malone FR, Leisenring W, Schoch G, et al. Prolonged anorexia and elevated plasma cytokine levels following myeloablative allogeneic hematopoietic cell transplant. Bone Marrow Transplant 2007; 40: 765-772.
45. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008; 358: 2482-2494.
46. Osowski CL, Dix SP, Lynn M, et al. An open-label dose comparison study of ondansetron for the prevention of emesis associated with chemotherapy prior to bone marrow transplantation. Support Care Cancer 1998; 6: 511-517.
47. Rubenstein EB. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol 2004; 2: 284-289.
48. Stiff PJ, Fox-Geiman MP, Kiley K, et al. Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transplant 2013; 19: 49-55.e1.
49. Wu D, Hockenbery DM, Brentnall TA, et al. Persistent nausea and anorexia after marrow transplantation: a prospective study of 78 patients. Transplantation 1998; 66: 1319-1324.
50. Ponec RJ, Hackman RC, McDonald GB. Endoscopic and histologic diagnosis of intestinal graft-vs.-host disease after marrow transplantation. Gastrointest Endosc 1999; 49: 612-621.
51. Washington K, Jagasia M. Pathology of graft-versus-host disease in the gastrointestinal tract. Hum Pathol 2009; 40: 909-917.
52. Ross WA, Ghosh S, Dekovich AA, et al. Endoscopic biopsy diagnosis of acute gastrointestinal graft-versus-host disease: rectosigmoid biopsies are more sensitive than upper gastrointestinal biopsies. Am J Gastroenterol 2008; 103: 982-989.
53. Cheung DY, Kim JI, Kim SS, et al. Endoscopic evaluation in gastrointestinal graftversus- host disease: comparisons with histological findings. Dig Dis Sci 2008; 53: 2947-2954.
54. Hockenbery DM, Cruickshank S, Rodell TC, et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prenisone-sparing therapy for gastrointestinal graft-versus-host diesease. Blood 2007; 109: 4557-4563.
55. Mielcarek M, Storer BE, Boeckh M, et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood 2009; 113: 2888-2894.
56. Holmberg L, Kikuchi K, Gooley TA, et al. Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 2006; 12: 226-234.
57. van Burik JA, Lawatsch EJ, DeFor TE, Weisdorf DJ. Cytomegalovirus enteritis among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2001; 7: 674-679.
58. Milano F, Pergam SA, Xie H, et al. Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. Blood 2011; 118: 5689-5696.
59. Charuhas PM, Fosberg KL, Bruemmer B, et al. A double-blind randomized trial comparing outpatient parenteral nutrition with intravenous hydration: effect on resumption of oral intake after marrow transplantation. J Parenter Enteral Nutr 1997; 21: 157-161.
60. Gooley TA, Rajvanshi P, Schoch HG, McDonald GB. Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation. Hepatology 2005; 41: 345-352.
61. Barba P, Martino R, Perez-Simon JA, et al. Incidence, characteristics and risk factors of marked hyperbilirubinemia after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2012; 47: 1343-1349.
62. Leisenring W, Martin P, Petersdorf E, et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood 2006; 108: 749-755.
63. Castilla-Llorente C, Martin PJ, McDonald GB, et al. Prognostic factors and outcomes of severe gastrointestinal graft-vs-host disease after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation 2014; 49: 966-971.
64. McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003; 101: 2043-2048.
65. Meresse V, Hartmann O, Vassal G, et al. Risk factors of hepatic venocclusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant 1992; 10: 135-141.
66. Rezvani AR, McCune JS, Storer BE, et al. Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: Pharmacokinetics and clinical outcomes. Biology of Blood and Marrow Transplantation 2013; 19: 1033-1039.
67. Carreras E, Diaz-Beya M, Rosinol L, et al. The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transplant 2011; 17: 1713-1720.
68. Corbacioglu S, Cesaro S, Faraci M, et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 2012; 379: 1301-1309.
69. Ruutu T, Eriksson B, Remes K, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100: 1977-1983.
70. Tay J, Tinmouth A, Fergusson D, et al. Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 206-217.
71. McDonald GB, Hinds MS, Fisher LB, et al. Venocclusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
72. Coppell JA, Richardson PG, Soiffer R, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant 2010; 16: 157-168.
73. Sakai M, Strasser SI, Shulman HM, et al. Severe hepatocellular injury after hematopoietic cell transplant: incidence, etiology and outcome. Bone Marrow Transplant 2009; 44: 441-447.
74. Carreras E, Granena A, Navasa M, et al. Transjugular liver biopsy in bone marrow transplantation. Bone Marrow Transplant 1993; 11: 21-26.
75. Shulman HM, Gooley T, Dudley MD, et al. Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation 1995; 59: 1015-1022.
76. Deleve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: Sinusoidal obstruction syndrome (venocclusive disease). Semin Liver Dis 2002; 22: 27-41.
77. Shulman HM, Fisher LB, Schoch HG, et al. Venocclusive disease of the liver after marrow transplantation: histologic correlates of clinical signs and symptoms. Hepatology 1994; 19: 1171-1180.
78. Bearman SI, Anderson GL, Mori M, et al. Venocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993; 11: 1729-1736.
79. McDonald GB. Hepatic vascular pathology after hematopoietic cell transplantation: sinusoidal obstruction syndrome, focal nodular hyperplasia, and nodular regenerative hyperplasia In: DeLeve LD, Garcia-Tsao G (eds.) Vascular Liver Disease: Mechanisms and Management. New York, NY: Springer, 2011, pp. 149-163.
80. McCune JS, Batchelder A, Guthrie KA, et al. Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy. Clin Pharmacol Ther 2009; 85: 615-622.
81. DeLeve LD, Wang X. Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes. Pharmacology 2000; 60: 143-154.
82. Jenke A, Freiberg-Richter J, Wilhelm S, et al. Accidental busulfan overdose during conditioning for stem cell transplantation. Bone Marrow Transplant 2005; 35: 125-128.
83. Nagler A, Labopin M, Berger R, et al. Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome. Bone Marrow Transplantation 2014; 49: 628-633.
84. Nath CE, Shaw PJ, Trotman J, et al. Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. Br J Clin Pharmacol 2010; 69: 484-497.
85. Abbasi N, Vadnais B, Knutson JA, et al. Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients. J Clin Pharmacol 2011; 51: 1429-1438.
86. de Lima M, Couriel D, Thall PF, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857-864.
87. Geddes M, Kangarloo SB, Naveed F, et al. High busulfan exposure is associated with worse outcomes in a daily IV busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 2008; 14: 220-228.
88. Puig N, de la Rubia J, Remigia MJ, et al. Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma 2006; 47: 1488-1494.
89. Yeh RF, Pawlikowski MA, Blough DK, et al. Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2012; 18: 265-272.
90. Richardson PG, Soiffer RJ, Antin JH, et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant 2010; 16: 1005-1017.
91. Richardson PG, Corbacioglu S, Ho VT, et al. Drug safety evaluation of defibrotide. Expert Opin Drug Saf 2013; 12: 123-136.
92. Bunin N, Guzikowski V, Rand ER, et al. Solid organ transplants following hematopoietic stem cell transplant in children. Pediatr Transplant 2010; 14: 1030-1035.
93. Chand N, Sanyal AJ. Sepsis-induced cholestasis. Hepatology 2007; 45: 230-241.
94. Shulman HM, Sharma P, Amos D, et al. A coded histologic study of hepatic graftversus- host disease after human bone marrow transplantation. Hepatology 1988; 8: 463-470.
95. Quaranta S, Shulman HM, Paganin S, et al. Autoantibodies in human chronic graft-versus-host disease after hematopoietic cell transplantation. Clin Immunol 1999; 91: 106-116.
96. Strasser SI, Shulman HM, Flowers ME, et al. Chronic graft-vs-host disease of the liver: presentation as an acute hepatitis. Hepatology 2000; 32: 1265-1271.
97. Akpek G, Boitnott JK, Lee LA, et al. Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion. Blood 2002; 100: 3903-3907.
98. Mayer J, Krejci M, Pospisil Z, et al. Successful treatment of steroid-refractory hepatitic variant of liver graft-vs-host disease with pulse cyclophosphamide. Exp Hematol 2009; 37: 767-773.
99. Kamar N, Bendall R, Legrand-Abravanel F, et al. Hepatitis E. Lancet 2012; 379: 2477-2488.
100. le Coutre P, Meisel H, Hofmann J, et al. Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation. Gut 2009; 58: 699-702.
101. Yagi T, Karasuno T, Hasegawa T, et al. Acute abdomen without cutaneous signs of varicella zoster virus infection as a late complication of allogeneic bone marrow transplantation: importance of empiric therapy with acyclovir. Bone Marrow Transplant 2000; 25: 1003-1005.
102. Vyas JM, Marasco WA. Fatal fulminant hepatic failure from adenovirus in allogeneic bone marrow transplant patients. Case Rep Infect Dis 2012; 2012: 463569.
103. Neofytos D, Ojha A, Mookerjee B, et al. Treatment of adenovirus disease in stem cell transplant recipients with cidofovir. Biol Blood Marrow Transplant 2007; 13: 74-81.
104. Muller WJ, Levin MJ, Shin YK, et al. Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients. Clin Infect Dis 2005; 41: 1812-1816.
105. Lau GK, He M-L, Fong DYT, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002; 36: 702-709.
106. Tsang SW, Chan HL, Leung NW, et al. Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection. Aliment Pharmacol Ther 2001; 15: 1737-1744.
107. Hui CK, Cheung WWW, Au WY, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005; 54: 1597-1603.
108. Lin P-C, Poh S-B, Lee M-Y, et al. Fatal fulminant hepatitis B after withdrawal of prophylactic lamivudine in hematopoietic stem cell transplantation patients. Int J Hematol 2005; 81: 349-351.
109. Arcaini L, Vallisa D, Rattotti S, et al. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Annals of Oncology 2014; 25:1404-1410.
110. Garg Garg V, van Heeswijk R, Lee JE, et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-27.
111. Hulskotte E, Gupta S, Xuan F, et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012; 56: 1622-1630.
112. Coilly A, Roche B, Dumortier J, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. Journal of Hepatology 2014; 60: 78-86.
113. Tischer S, Fontana RJ. Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. Journal of Hepatology 2014; 60: 872-884.
114. Peffault de Latour R, Asselah T, Levy V, et al. Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 2005; 36: 709-713.
115. van Burik JH, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis: an autopsy study of 355 patients. Medicine (Baltimore) 1998; 77: 246-254.
116. Marotta G, Tozzi M, Sammassimo S, et al. Complete resolution of hepatic aspergillosis after non-myeloablative hematopoietic stem cell transplantation in a patient with acute myeloid leukemia. Hematology 2005; 10: 383-386.
117. Ko CW, Murakami C, Sekijima JH, et al. Chemical composition of gallbladder sludge in patients after marrow transplantation. Am J Gastroenterol 1996; 91: 1207-1210.
118. Ko CW, Gooley T, Schoch HG, et al. Acute pancreatitis in marrow transplant patients: prevalence at autopsy and risk factor analysis. Bone Marrow Transplant 1997; 20: 1081-1086.
119. Murakami CS, Louie W, Chan GS, et al. Biliary obstruction in hematopoietic cell transplant recipients: an uncommon diagnosis with specific causes. Bone Marrow Transplantation 1999; 23: 921-927.
120. Alnusair MM, DeMagalhaes-Silverman M, Silverman WB. The role of ERCP in patients with pancreatico-biliary problems in the setting of hematopoietic stem cell transplant. Gastrointest Endosc 2006; 63: 655-659.
121. Kim HN, Alousi AM, Lee JH, et al. Role of ERCP in patients after hematopoietic stem cell transplantation. Gastrointest Endosc 2011; 74: 817-824.
122. Frere P, Canivet JL, Gennigens C, et al. Hyperammonemia after high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplant 2000; 26: 343-345.
123. Summar ML, Barr F, Dawling S, et al. Unmasked adult-onset urea cycle disorders in the critical care setting. Crit Care Clin 2005; 21: S1-S8.
124. Schwartz JM, Wolford JL, Thornquist MD, et al. Severe gastrointestinal bleeding after marrow transplantation, 1987-1997: incidence, causes, and outcome. Am J Gastroenterol 2001; 96: 385-393.
125. Barker CC, Anderson RA, Sauve RS, Butzner JD. GI complications in pediatric patients post-BMT. Bone Marrow Transplant 2005; 36: 51-58.
126. Spencer GD, Shulman HM, Myerson D, et al. Diffuse intestinal ulceration after marrow transplantation: a clinical-pathological study of 13 patients. Hum Pathol 1986; 17: 621-633.
127. Selinger RRE, McDonald GB, Hockenbery DM, et al. Efficacy of neodymium:YAG laser therapy for gastric antral vascular ectasia (GAVE) following hematopoietic cell transplant. Bone Marrow Transplant 2006; 37: 191-197.
128. Congly SE, Gao ZH, Storr M. Duodenal vascular ectasia (DUVE) associated with hematopoietic stem cell transplant. Endoscopy 2011; 43(Suppl. 2 UCTN): E197-E198.
129. Schmidmaier R, Bittmann I, Gotzberger M, Straka C, et al. Vascular ectasia of the whole intestine as a cause of recurrent gastrointestinal bleeding after high-dose chemotherapy. Endoscopy 2006; 38: 940-942.
130. Kumar S, Dispenzieri A, Lacy MQ, et al. High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis. Bone Marrow Transplant 2001; 28: 381-385.
131. Ohashi K, Sanaka M, Tanaka Y, et al. Use of octreotide in the management of severe duodenal bleeding after unrelated-donor bone marrow transplantation. Int J Hematol 2003; 78: 176-177.
132. McDonald GB, Steinbach G. Gastrointestinal infections after solid organ or hematopoietic cell transplantation. In: Bowden RA, Ljungman P, Snydman DR (eds.) Transplant Infections, 3rd edn. Philadelphia, PA: Lippincott Williams & Wilkens, 2010, pp. 236-255.
133. Tran HAM, Vincent JM, Slavin MA, Grigg A. Esophageal perforation secondary to angio-invasive Candida glabrata following hemopoietic stem cell transplantation. Clin Microbiol Infect 2003; 9: 1215-1218.
134. Stemmelin GR, Pest P, Peters RA, et al. Severe esophageal stricture after autologous bone marrow transplant [Letter]. Bone Marrow Transplant 1995; 15: 1001-1002.
135. Eom CS, Jeon CY, Lim JW, et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011; 183: 310-319.
136. Kwok CS, Arthur AK, Anibueze CI, et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012; 107: 1011-1019.
137. Hiller N, Zagal I, Hadas-Halpern I. Spontaneous intramural hematoma of the esophagus. Am J Gastroenterol 1999; 94: 2282-2284.
138. Restrepo CS, Lemos DF, Ocazionez D, et al. Intramural hematoma of the esophagus: a pictorial essay. Emerg Radiol 2008; 15: 13-22.
139. Otero Lopez-Cubero S, Sale GE, McDonald GB. Acute graft-versus-host disease of the esophagus. Endoscopy 1997; 29: S35-S36.
140. Crouch MA, Restino MS, Cruz JM, et al. Octreotide acetate in refractory bone marrow transplant-associated diarrhea. Ann Pharmacother 1996; 30: 331-336.
141. Goldberg J, Jacobsohn DA, Zahurak ML, Vogelsang GB. Gastrointestinal toxicity from the preparative regimen is associated with an increased risk of graft-versushost disease. Biol Blood Marrow Transplant 2005; 11: 101-107.
142. Liu D, Yan C, Xu L, et al. Diarrhea during the conditioning regimen is correlated with the occurrence of severe acute graft-versus-host disease through systemic release of inflammatory cytokines. Biol Blood Marrow Transplant 2010; 16: 1567-1575.
143. Cox GJ, Matsui SM, Lo RS, et al. Etiology and outcome of diarrhea after marrow transplantation: a prospective study. Gastroenterology 1994; 107: 1398-1407.
144. Martinez C, Rosales M, Calvo X, et al. Serial intestinal endoscopic examinations of patients with persistent diarrhea after allo-SCT. Bone Marrow Transplant 2012; 47: 694-699.
145. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756-762.
146. Rezvani AR, Storer BE, Storb RF, et al. Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011; 17: 1594-1601.
147. Coy DL, Ormazabal A, Godwin JD, Lalani T. Imaging evaluation of pulmonary and abdominal complications following hematopoietic stem cell transplantation. Radiographics 2005; 25: 305-317.
148. Schmit M, Bethge W, Beck R, et al. CT of gastrointestinal complications associated with hematopoietic stem cell transplantation. AJR Am J Roentgenol 2008; 190: 712-719.
149. Gorg C, Wollenberg B, Beyer J, et al. High-resolution ultrasonography in gastrointestinal graft-versus-host disease. Ann Hematol 2005; 84: 33-39.
150. Schreyer AG, Landfried K, Jung EM, et al. Contrast-enhanced ultrasound for differential diagnosis of suspected GvHD in patients after allogeneic transplantation. Clin Hemorheol Microcirc 2011; 49: 129-136.
151. Hepgur M, Ahluwalia MS, Anne N, et al. Medical management of pneumatosis intestinalis in patients undergoing allogeneic blood and marrow transplantation. Bone Marrow Transplant 2011; 46: 876-879.
152. Kreisel W, Dahlberg M, Bertz H, et al. Endoscopic diagnosis of acute intestinal GVHD following allogeneic hematopoietic SCT: a retrospective analysis in 175 patients. Bone Marrow Transplant 2012; 47: 430-438.
153. Thompson B, Salzman D, Steinhauer J, et al. Prospective endoscopic evaluation for gastrointestinal graft-versus-host disease: determination of the best diagnostic approach. Bone Marrow Transplant 2006; 38: 371-376.
154. Neumann S, Schoppmeyer K, Lange T, et al. Wireless capsule endoscopy for diagnosis of acute intestinal graft-versus-host disease. Gastrointest Endosc 2007; 65: 403-409.
155. Van Lint MT, Milone G, Leotta S, et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 2006; 107: 4177-4181.
156. Levine JE, Logan BR, Wu J, et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood 2012; 119: 3854-3860.
157. Harris AC, Ferrara JL, Braun TM, et al. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood 2012; 119: 2960-2963.
158. Rodriguez-Otero P, Porcher R, Peffault de Latour R, et al. Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease. Blood 2012; 119: 5909-5917.
159. MacMillan ML, Robin M, Harris AC, et al. A refined risk score for acute Graftversus- Host Disease that predicts response to Initial therapy, survival, and transplant- related mortality. Biol Blood Marrow Transplant 2015; 21: 761-767.
160. Paczesny S. Discovery and validation of graft-versus-host disease biomarkers. Blood 2013; 121: 585-594.
161. Levine JE, Braun TM, Harris AC, et al. A prognostic score for acute graft-versushost disease based on biomarkers: A multicenter study. The Lancet Haematology 2015; 2: e21-e9.
162. Vander Lugt MT, Braun TM, Hanash S, et al. ST2 as a marker for risk of therapyresistant graft-versus-host disease and death. N Engl J Med 2013; 369: 529-539.
163. Ponce DM, Hilden P, Mumaw C, et al. High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. Blood 2015; 125: 199-205.
164. Holtan SG, Verneris MR, Schultz KR, et al. Circulating angiogenic factors associated with response and survival in patients with acute Graft-versus-Host Disease: Results from Blood and Marrow Transplant Clinical Trials Network 0302 and Biol Blood Marrow Transplant 2015, in press.
165. McDonald GB, Tabellini L, Storer BE, et al. Plasma biomarkers of acute GVHD and non-relapse mortality: Predictive value of measurements before GVHD onset and treatment. Blood 2015, in press.
166. Kamboj M, Mihu CN, Sepkowitz K, et al. Work-up for infectious diarrhea after allogeneic hematopoietic stem cell transplantation: single specimen testing results in cost savings without compromising diagnostic yield. Transpl Infect Dis 2007; 9: 265-269.
167. Collini PJ, Bauer M, Kuijper E, Dockrell DH. Clostridium difficile infection in HIV-seropositive individuals and transplant recipients. J Infect 2012; 64: 131-147.
168. Sebire NJ, Malone M, Shah N, et al. Pathology of astrovirus associated diarrhoea in a paediatric bone marrow transplant recipient. J Clin Pathol 2004; 57: 1001-1003.
169. Ison MG. Adenovirus infections in transplant recipients. Clin Infect Dis 2006; 43: 331-339.
170. Robin M, Marque-Juillet S, Scieux C, et al. Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome. Haematologica 2007; 92: 1254-1257.
171. Symeonidis N, Jakubowski A, Pierre-Louis S, et al. Invasive adenoviral infections in T-cell-depleted allogeneic hematopoietic stem cell transplantation: high mortality in the era of cidofovir. Transpl Infect Dis 2007; 9: 108-113.
172. Mori T, Mori S, Kanda Y, et al. Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 33: 431-434.
173. Operario DJ, Houpt E. Defining the causes of diarrhea: novel approaches. Curr Opin Infect Dis 2011; 24: 464-471.
174. Detrait M, Poirier L, Roy DC, et al. Diphyllobothriasis, a rare cause of profuse diarrhea following autologous transplantation. Bone Marrow Transplant 2009; 44: 131-132.
175. Wirk B, Wingard JR. Strongyloides stercoralis hyperinfection in hematopoietic stem cell transplantation. Transpl Infect Dis 2009; 11: 143-148.
176. Yamazaki R, Mori T, Nakazato T, et al. Non-tuberculous mycobacterial infection localized in small intestine developing after allogeneic bone marrow transplantation. Intern Med 2010; 49: 1191-1193.
177. Nicholson O, Feja K, LaRussa P, et al. Nontuberculous mycobacterial infections in pediatric hematopoietic stem cell transplant recipients: case report and review of the literature. Pediatr Infect Dis J 2006; 25: 263-267.
178. Joshi NM, Hassan S, Jasani P, et al. Bile acid malabsorption in patients with graftversus- host disease of the gastrointestinal tract. Br J Haematol 2012; 157: 403-407.
179. Nieto Y, Russ P, Everson G, et al. Acute pancreatitis during immunosuppression with tacrolimus following an allogeneic umbilical cord blood transplantation. Bone Marrow Transplant 2000; 26: 109-111.
180. Grigg AP, Angus PW, Hoyt R, Szer J. The incidence, pathogenesis and natural history of steatorrhea after bone marrow transplantation. Bone Marrow Transplant 2003; 31: 701-703.
181. Inamoto Y, Ito M, Suzuki R, et al. Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy. Bone Marrow Transplant 2009; 44: 43-49.
182. Maes BD, Dalle I, Geboes K, et al. Erosive enterocolitis in mycophenolate mofetiltreated renal-transplant recipients with persistent afebrile diarrhea. Transplantation 2003; 75: 665-672.
183. Ortega F, Sanchez-Fructuoso A, Cruzado JM, et al. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium. Transplantation 2011; 92: 426-432.
184. Herrera AF, Soriano G, Bellizzi AM, et al. Cord colitis syndrome in cord-blood stem-cell transplantation. N Engl J Med 2011; 365: 815-824.
185. Milano F, Shulman HM, Guthrie KA, et al. Late onset colitis after cord blood transplant is consistent with Graft-Versus-Host Disease: Results of a blinded histopathological review. Biology of Blood and Marrow Transplantation 2014; 20: 1008-1013.
186. Jones AD, Maziarz R, Gilster J, et al. Surgical complications of bone marrow transplantation. Am J Surg 2003; 185: 481-484.
187. de Magalhaes-Silverman M, Simpson J, Ball E. Pneumoperitoneum without peritonitis after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 1998; 21: 1153-1154.
188. Cabana MD, Alavi A, Berlin JA, et al. Morphine-augmented hepatobiliary scintigraphy: a meta-analysis. Nucl Med Commun 1995; 16: 1068-1671.
189. Koc Y, Miller KB, Schenkein DP, et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant 2000; 6: 44-49.
190. Kalantari BN, Mortele KJ, Cantisani V, et al. CT features with pathologic correlation of acute gastrointestinal graft-versus-host disease after bone marrow transplantation in adults. AJR Am J Roentgenol 2003; 181: 1621-1625.
191. McIlwaine LM, Fitzsimons EJ, Soutar RL. Inappropriate antidiuretic hormone secretion, abdominal pain and disseminated varicella-zoster virus infection: an unusual and fatal triad in a patient 13 months post rituximab and autologous stem cell transplantation. Clin Lab Haematol 2001; 23: 253-254.
192. McCullough KD, McDonald GB. Neutropenic enterocolitis. Curr Treat Options Infect Dis 2003; 5: 367-375.
193. Schlatter M, Snyder K, Freyer D. Successful nonoperative management of typhlitis in pediatric oncology patients. J Pediatr Surg 2002; 37: 1151-1155.
194. Yuan C-S, Israel RJ. Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects. Expert Opin Investig Drugs 2006; 15: 541-552.
195. Ponec RJ, Saunders MD, Kimmey MB. Neostigmine for the treatment of acute colonic pseudo-obstruction. N Engl J Med 1999; 341: 137-141.
196. Schwartz DA, Harewood GC, Wiersema MJ. EUS for rectal disease. Gastrointest Endosc 2002; 56: 100-109.
197. Ganguly N, Waller S, Stasik CJ, et al. Giant anal condylomatosis after allogeneic bone marrow transplantation: a rare complication of human papilloma virus infection. Transpl Infect Dis 2008; 10: 56-58.
198. Sakai M, McDonald GB. Gastrointestinal and hepatic manifestations of chronic graft versus host disease. In: Vogelsang GB, Pavletic SZ (eds.) Chronic Graft versus Host Disease. New York, NY: Cambridge Unviersity Press, 2009, pp. 216-228.
199. McDonald GB, Sullivan KM, Schuffler MD, et al. Esophageal abnormalities in chronic graft-versus-host disease in humans. Gastroenterology 1981; 80: 914-921.
200. Mackey JR, Desai S, Larratt L, et al. Myasthenia gravis in association with allogeneic bone marrow transplantation: clinical observations, therapeutic implications and review of literature. Bone Marrow Transplant 1997; 19: 939-942.
201. Aceves SS, Bastian JF, Newbury RO, Dohil R. Oral viscous budesonide: a potential new therapy for eosinophilic esophagitis in children. Am J Gastroenterol 2007; 102: 2271-2279.
202. Alexander JA, Jung KW, Arora AS, et al. Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2012; 10: 742-749.
203. Yokota A, Ozawa S, Masanori T, et al. Secondary solid tumors after allogeneic hematopoietic SCT in Japan. Bone Marrow Transplant 2012; 47: 95-100.
204. Iyer RV, Hahn T, Roy HN, et al. Long-term use of oral beclomethasone dipropionate for the treatment of gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11: 587-592.
205. Villanueva FN, Perez-Simon JA, Silva FF, et al. Oral beclomethasone dipropionate for the treatment of gastrointestinal chronic graft-versus-host disease. Biol Blood Marrow Transplant 2009; 15: 1331-1336.
206. Velasco Guardado A, Lopez-Corral L, Perez-Simon JA, et al. Helicobacter pylori infection and graft-versus-host disease. Biol Blood Marrow Transplant 2011; 17: 765-769.
207. Yoon JY, Kim H, Kang HJ, et al. Chronic graft versus host disease with small bowel obstruction after unrelated hematopoietic stem cell transplantation in a patient with acute myeloid leukemia. Korean J Hematol 2012; 47: 142-145.
208. Borgaonkar MR, Duggan PR, Adams G. Differing clinical manifestations of celiac disease transmitted by bone marrow transplantation. Dig Dis Sci 2006; 51: 210-212.
209. Kamble R, Selby G, Mims M, et al. Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 506-510.
210. Fried RH, Murakami CS, Fisher LD, et al. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann Intern Med 1992; 116: 624-629.
211. Arat M, Idilman R, Soydan EA, et al. Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver. Clin Transplant 2005; 19: 798-803.
212. Daley-Yates PT, Price AC, Sisson JR, et al. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 2001; 51: 400-409.
213. Shimizu T, Kasahara M, Tanaka K. Living-donor liver transplantation for chronic hepatic graft-versus-host disease. N Engl J Med 2006; 354: 1536-1537.
214. Englert C, Ganschow R. Liver transplantation in a child with liver failure due to chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from the same unrelated living donor. Pediatr Transplant 2012; 16: E325-E327.
215. Xhaard A, Nahon P, Robin M, et al. Hepatic GVHD leading to cirrhosis after allogeneic hematopoietic SCT. Bone Marrow Transplant 2012; 47: 1484-1485.
216. Mullighan CG, Bogdanos DP, Vergani D, Bardy PG. Cytochrome P450 1A2 is a target antigen in hepatitic graft-versus-host disease. Bone Marrow Transplant 2006; 38: 703-705.
217. Ljungman P, Locasciulli A, de Soria VG, et al. Long-term follow-up of HCVinfected hematopoietic SCT patients and effects of antiviral therapy. Bone Marrow Transplant 2012; 47: 1217-1221.
218. Peffault de Latour R, Levy V, Asselah T, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 2004; 103: 1618-1624.
219. Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002; 100: 17-21.
220. Nieters A, Kallinowski B, Brennan P, et al. Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. Gastroenterology 2006; 131: 1879-1886.
221. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection. Aliment Pharmacol Ther 2005; 21: 653-662.
222. Andreoni KA, Lin JI, Groben PA. Liver transplantation 27 years after bone marrow transplantation from the same living donor. N Engl J Med 2004; 350: 2624-2625.
223. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
224. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
225. Liaw Y-F, Kao J-H, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6: 531-561.
226. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539.
227. Chan HL, Wong GL, Choi PC, et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat 2009; 16: 36-44.
228. Lok AS, Ward JW, Perrillo RP, et al. Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable. Ann Intern Med 2012; 156: 743-745.
229. Strasser SI, Sullivan KM, Myerson D, et al. Cirrhosis of the liver in long-term marrow transplant survivors. Blood 1999; 93: 3259-3266.
230. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
231. Bissonnette J, Genereux A, Cote J, et al. Hepatic hemodynamics in 24 patients with nodular regenerative hyperplasia and symptomatic portal hypertension. J Gastroenterol Hepatol 2012; 27: 1336-1340.
232. Plessier A, Rautou PE, Valla DC. Management of hepatic vascular diseases. J Hepatol 2012; 56(Suppl. 1): S25-S38.
233. Sudour H, Mainard L, Baumann C, et al. Focal nodular hyperplasia of the liver following hematopoietic SCT. Bone Marrow Transplant 2009; 43: 127-132.
234. Donati F, Boraschi P, Gigoni R, et al. Focal nodular hyperplasia of the liver: diffusion and perfusion MRI characteristics. Magn Reson Imaging 2013; 31: 10-16.
235. Oliver MR, Van Voorhis WC, Boeckh M, et al. Hepatic mucormycosis in a bone marrow transplant recipient who ingested naturopathic medicine. Clin Infect Dis 1996; 22: 521-524.
236. Sastry J, Young S, Shaw PJ. Acute pancreatitis due to tacrolimus in a case of allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 33: 867-868.
237. Akpek G, Valladares JL, Lee L, et al. Pancreatic insufficiency in patients with chronic graft-versus-host disease. Bone Marrow Transplant 2001; 27: 163-166.
238. Radu B, Allez M, Gornet JM, et al. Chronic diarrhoea after allogenic bone marrow transplantation. Gut 2005; 54: 161-174.
239. Noetzli LJ, Carson SM, Nord AS, et al. Longitudinal analysis of heart and liver iron in thalassemia major. Blood 2008; 112: 2973-2978.
240. Carpenter JP, He T, Kirk P, et al. On T2* magnetic resonance and cardiac iron. Circulation 2011; 123: 1519-1528.
241. Strasser SI, Kowdley KV, Sale GE, McDonald GB. Iron overload in bone marrow transplant recipients. Bone Marrow Transplant 1998; 22: 167-173.
242. Lucarelli G, Angelucci E, Giardini C, et al. Fate of iron stores in thalassaemia after bone-marrow transplantation. Lancet 1993; 342: 1388-1391.
243. Chotsampancharoen T, Gan K, Kasow KA, et al. Iron overload in survivors of childhood leukemia after allogeneic hematopoietic stem cell transplantation. Pediatr Transplant 2009; 13: 348-352.
244. Angelucci E, Muretto P, Lucarelli G, et al. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients. Blood 1997; 90: 994-998.
245. Chow EJ, Mueller BA, Baker KS, et al. Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation. Ann Intern Med 2011; 155: 21-32.
246. Chacko J, Pennell DJ, Tanner MA, et al. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol 2007; 138: 587-593.
247. Armand P, Kim HT, Rhodes J, et al. Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 852-860.
248. Majhail NS, Lazarus HM, Burns LJ. A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant 2010; 16: 832-837.
249. Zacharski LR, Chow BK, Howes PS, et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008; 100: 996-1002.
250. Edgren G, Reilly M, Hjalgrim H, et al. Donation frequency, iron loss, and risk of cancer among blood donors. J Natl Cancer Inst 2008; 100: 572-579.
251. Lowe T, Bhatia S, Somlo G. Second malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007; 13: 1121-1134.
252. Rizzo JD, Curtis RE, Socié G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 1175-1183.